'김갑성' 기자의 전체기사
-
YolTech Therapeutics Raises $45 Million in Series B Financ…
SHANGHAI, Sept. 11, 2025 -- YolTech Therapeutics, a clinical-stage biotech company pioneering in vivo genome editing therapies, today announced the closing of its approximately $45 million Series B financing led by the AstraZeneca-CICC healthcare investment fund. The proceeds will support the advancement of YolTech's clinical programs and global strategic execution. Dr. Yuxuan Wu, Founder and CEO of YolTech, "This financing marks an important milestone as we continue advancing our pipeline toward transformative therapies. We are committed to turning cutting-edge gene-editing scien
- 김갑성 기자
- 2025-09-11 20:05
-
Kazia Therapeutics Reports Complete Ex Vivo Disruption of L…
SYDNEY, Sept. 11, 2025 -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced new findings from a collaborative research program led by Professor Sudha Rao at QIMR Berghofer. In this ex vivo study, blood samples from Stage IV HER2-positive metastatic breast cancer (mBC) patients were profiled to evaluate the effect of paxalisib, Kazia's investigational PI3K–mTOR inhibitor, on metastatic burden. Paxalisib monotherapy demonstrated a statistically significant reduction in single circulating tumor cells and achieved a complete (100%) dis
- 김갑성 기자
- 2025-09-11 20:00
-
Lundbeck showcases new clinical migraine data, includi…
[ 메디채널 김갑성 기자 ] Lundbeck demonstrates leadership and unwavering commitment to advancing migraine management and supporting patient outcomes with six presentations at the 2025 International Headache Congress (IHC), including three oral presentations on eptinezumab (Vypeti®) and Lu AG09222 (anti-PACAP mAb) New data from the open-label extension of the RESOLUTION trial and the primary results of the SUNSET extension trial will be presented for the first time at IHC1,2 Patients treated with eptinezumab experienced sustained reductions in migraine symptom and burden, including long-term r
- 김갑성 기자
- 2025-09-11 14:56
-
HaemaLogiX wins "Most Promising CAR-T Pipeline in APAC" at th…
SYDNEY, Sept. 11, 2025 -- HaemaLogiX Ltd, a clinical stage Australian biotech, developing novel immunotherapies for patients with blood cancers and B-cell diseases, was honoured to be awarded the "Most Promising CAR-T Pipeline in APAC" at the Asia Pacific CGT Excellence Awards 2025, held in Singapore last night. The award recognises companies demonstrating outstanding innovation, scientific excellence, and translational potential in the rapidly evolving CAR T therapy sector. This accolade highlights HaemaLogiX's role as a leader in advancing CAR T-cell therapies that
- 김갑성 기자
- 2025-09-11 11:52
-
Amaran Biotech Wins Asia-Pacific Biologics CDMO Excellence…
[ 메디채널 김갑성 기자 ] 50-Person Team Demonstrates Taiwan's Biotech Strength HSINCHU, Sept. 11, 2025 -- Amaran Biotech, a next-generation Contract Development and Manufacturing Organization (CDMO), was awarded the "Best Fill-Finish" at the 2025 Asia-Pacific Biologics CDMO Excellence Awards held in Singapore on September 10. This honor recognizes Amaran Biotech's leading capabilities in aseptic fill-finish processes and marks an important step for Taiwan's biotech industry on the international stage. The Asia-Pacific Biologics CDMO Excellence Awards, organized by the renowne
- 김갑성 기자
- 2025-09-11 10:00
-
SynbioTech's TWK10 Approved to Boost Muscle Strength, Th…
BANGKOK, Sept. 11, 2025 -- SynbioTech Inc., ranked among the world's top 20 probiotic suppliers, is the leader in functional probiotics for muscle and joint health, sports, women's wellness, and immune support. Its patented flagship probiotic, Lactiplantibacillus plantarum TWK10®, has earned multiple awards in Europe, the US and Japan, with clinical trials showing increased muscle mass and reduced body fat. In 2024, TWK10® was approved by the Thai government as an edible strain, making it a key focus in the Thai market. SynbioTech will showcase this and other flagship probiotics at Vi
- 김갑성 기자
- 2025-09-11 10:00
-
Allianz Partners appoints Okan Özdemir as its new Chief Offic…
BRISBANE, Australia, Sept. 11, 2025 -- Allianz Partners, a global leader in insurance and assistance services, is pleased to announce the appointment of Okan Özdemir as its new Chief Officer for Health and Board Member, effective September 1, 2025. In this role, Okan will report directly to Allianz Partners CEO Tomas Kunzmann. Okan Özdemir joins Allianz Partners from Allianz Türkiye, where he served as Chief Health Officer and Executive Board Member since 2019. With over 24 years of strong leadership at Allianz in a number of strategic roles including Ch
- 김갑성 기자
- 2025-09-11 07:00
-
XingImaging in partnership with SynuSight was awarded a gr…
NEW HAVEN, Conn., Sept. 11, 2025 -- XingImaging in partnership with SynuSight Biotech has received funding of $3.84M from The Michael J. Fox Foundation to conduct studies on 18F-FD4, a specific α-synuclein (α-syn)-targeted PET tracer. Based on prior investigator-initiated trials, the SynuSight Biotech developed technology, showed the potential to become the world's first α-syn-targeted PET tracer for Parkinson's disease (PD), multiple system atrophy (MSA), and rapid eye movement sleep behavior disorder (RBD). XingImaging is a leading neuroimaging and radiopharmaceutical service
- 김갑성 기자
- 2025-09-11 05:06
-
Health In Tech to Host Annual Meeting of Stockholders
STUART, Fla., Sept. 11, 2025 -- Health In Tech (Nasdaq: HIT) will host its 2025 Annual Stockholder Meeting on Friday, October 3, 2025, at 10:00 AM ET live via virtual webcast. To participate in the Annual Stockholders Meeting, stockholders should visit www.cleartrustonline.com/HIT or the Company's Investor Relations site at https://healthintech.investorroom.com/ under "News & Events," and enter the 12-digit control number found in the proxy materials. Guests may also access the Annual Shareholders Meeting in listen-only mode. No control number is re
- 김갑성 기자
- 2025-09-11 04:30
-
메타볼론, 차이나 카두리 바이오뱅크와 협력해 정밀의료 발전 추진
멀티오믹스 연구 통해 생활습관, 환경, 사회경제적, 유전적 요인이 일반 질환 형성에 얼마나 중요한 역할을 하는지 규명할 예정 모리스빌, 노스캐롤라이나주, 2025년 9월 11일 -- 광범위한 생명과학 연구, 진단, 치료제 개발 및 정밀의학 응용 발전에 앞장서는 대사체학(metabolomics) 솔루션 제공 분야 글로벌 선도기업 메타볼론(Metabolon)이 9일 차이나 카두리 바이오뱅크(China Kadoorie Biobank, 이하 CKB) 의뢰로 자사의 글로벌 디스커버리 패널™(Global Discovery Panel™)을 활용해 혈장 대사체학 바이오마커를 분석하기로 했다고 밝혔다. CKB는 생활습관과 환경 및 유전적•사회경제적 요인이 일반 질환 형성에 어떻게 중요한 역할을 하는지 조사하는 세계 최대 규모이자 가장 포괄적인 코호트 연구 중 하나다. CKB는 2004년부터 2008년 사이 옥스퍼드 대학교와 베이징 대학교 등이 포함된 중국 내 다양한 파트너 기관이 공동으로 추진해온 장기 협력 프로젝트다. 지금까지 임상 시험과 인구 건강 연구는 주로 백인 유럽인 참가자에 집중된 탓에 다른 인종과 민족 집단의 다양성은 간
- 김갑성 기자
- 2025-09-11 02:51
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-10-19_SUN
- Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting 15:00
- Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia 14:00
- From Wellbeing to Academics: Why HK Parents Are Hitting Pause on Kids' Social Media and Device Use 13:00
- 내면의 조화를 발견하세요: '원더풀 인도네시아 웰니스 페스티벌 2025' 개최 01:50
- 제2회 마나르 아부다비 출품 작가 명단 공개 00:48
- 중국-피지 어업 협력, 섬나라 경제 활력 끌어올리다 00:00
2025-10-18_SAT
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 10월 19일 16시 40분